✦ LIBER ✦

Efficacy and Safety of Valgancyclovir as Preemptive Therapy for the Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

✍ Scribed by C. Dı́az-Pedroche; C. Lumbreras; P. Del Valle; R. San Juan; S. Hernando; D. Folgueira; A. Andrés; J. Delgado; J.C. Meneu; J.M. Morales; E. Moreno; J.M. Aguado

Book ID: 116931834
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 51 KB
Volume: 37
Category: Article
ISSN: 0041-1345
DOI: 10.1016/j.transproceed.2005.10.075

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and Safety of Valganciclovir vs

Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

✍ Carlos Paya; Atul Humar; Ed Dominguez; Kenneth Washburn; Emily Blumberg; Barbara 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB

Preemptive Therapy With Intravenous Ganc

Preemptive Therapy With Intravenous Ganciclovir for the Prevention of Cytomegalovirus Disease in Lung Transplant Recipients

✍ V. Monforte; A. Román; J. Gavaldà; C. Bravo; P. Gispert; A. Pahissa; F. Morell 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Preemptive Therapy for the Prevention of

Preemptive Therapy for the Prevention of Cytomegalovirus Disease in Renal Transplant Recipients: Our Preliminary Experience

✍ N. Paudice; A. Mehmetaj; M. Zanazzi; L. Moscarelli; R. Piperno; L. Di Maria; E. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Preemptive therapy is not adequate for p

Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas–kidney transplant recipients

✍ F. López-Medrano; B. Rueda; M. Lizasoain; R. San Juan; D. Folgueira; A. Andrés; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB

Valganciclovir as preemptive therapy for

Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts

✍ Nina Singh; Cheryl Wannstedt; Lois Keyes; Debra Mayher; Lisa Tickerhoof; Mohamed 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus (CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient-negative/donor-positive (RϪ/Dϩ) liver transplant recipients. Of 187 consecutive liver transplant recipients at our institutio

Efficacy and safety of low-dose valganci

Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients

✍ Jeong M. Park; Kathleen D. Lake; Juan D. Arenas; Robert J. Fontana 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant recipients has not been established. We retrospectively compared the efficacy and safety of low-dose oral VGCV (450 mg once daily for 90 days) and standard oral ganciclovir (1 g three times a d